Celldex Therapeutics Net Income
| CLDX Stock | USD 23.00 0.06 0.26% |
As of the 18th of February 2026, Celldex Therapeutics shows the Standard Deviation of 3.12, insignificant risk adjusted performance, and Mean Deviation of 2.4. Celldex Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Celldex Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 363.12 | Revenue | Earnings Share (3.38) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -142.1 M | -135 M | |
| Net Loss | -142.1 M | -149.2 M | |
| Net Loss | -101.1 M | -106.1 M | |
| Net Loss | (2.21) | (2.32) | |
| Net Income Per E B T | 1.15 | 1.62 |
Celldex | Net Income | Build AI portfolio with Celldex Stock |
The evolution of Net Income for Celldex Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Celldex Therapeutics compares to historical norms and industry peers.
Latest Celldex Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Celldex Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Celldex Therapeutics financial statement analysis. It represents the amount of money remaining after all of Celldex Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Celldex Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (157.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Celldex Net Income Regression Statistics
| Arithmetic Mean | (98,531,151) | |
| Coefficient Of Variation | (45.63) | |
| Mean Deviation | 38,456,142 | |
| Median | (112,325,000) | |
| Standard Deviation | 44,960,922 | |
| Sample Variance | 2021.5T | |
| Range | 156.2M | |
| R-Value | (0.62) | |
| Mean Square Error | 1317.1T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (5,554,487) | |
| Total Sum of Squares | 32343.8T |
Celldex Net Income History
Other Fundumenentals of Celldex Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Celldex Therapeutics Net Income component correlations
Celldex Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Celldex Therapeutics is extremely important. It helps to project a fair market value of Celldex Stock properly, considering its historical fundamentals such as Net Income. Since Celldex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Celldex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Celldex Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. Projected growth potential of Celldex fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Celldex Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (3.38) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
Understanding Celldex Therapeutics requires distinguishing between market price and book value, where the latter reflects Celldex's accounting equity. The concept of intrinsic value - what Celldex Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Celldex Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Celldex Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Celldex Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Celldex Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Celldex Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Celldex Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Celldex Therapeutics.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Celldex Therapeutics on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Celldex Therapeutics or generate 0.0% return on investment in Celldex Therapeutics over 90 days. Celldex Therapeutics is related to or competes with Vera Therapeutics, Abcellera Biologics, Janux Therapeutics, Immunome, Biohaven Pharmaceutical, Spyre Therapeutics, and Uniqure NV. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific ant... More
Celldex Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Celldex Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Celldex Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 14.68 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 5.63 |
Celldex Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celldex Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Celldex Therapeutics' standard deviation. In reality, there are many statistical measures that can use Celldex Therapeutics historical prices to predict the future Celldex Therapeutics' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.05) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celldex Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celldex Therapeutics February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 2.4 | |||
| Coefficient Of Variation | (7,157) | |||
| Standard Deviation | 3.12 | |||
| Variance | 9.75 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 14.68 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 5.63 | |||
| Skewness | 0.1786 | |||
| Kurtosis | 0.0932 |
Celldex Therapeutics Backtested Returns
Celldex Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0316, which signifies that the company had a -0.0316 % return per unit of risk over the last 3 months. Celldex Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Celldex Therapeutics' Standard Deviation of 3.12, insignificant risk adjusted performance, and Mean Deviation of 2.4 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.06, which signifies a somewhat significant risk relative to the market. Celldex Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Celldex Therapeutics is expected to follow. At this point, Celldex Therapeutics has a negative expected return of -0.0971%. Please make sure to confirm Celldex Therapeutics' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Celldex Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.20 |
Weak predictability
Celldex Therapeutics has weak predictability. Overlapping area represents the amount of predictability between Celldex Therapeutics time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Celldex Therapeutics price movement. The serial correlation of 0.2 indicates that over 20.0% of current Celldex Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.2 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 1.7 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Celldex Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Celldex Therapeutics reported net income of (157.86 Million). This is 146.26% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 127.65% higher than that of the company.
Celldex Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celldex Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celldex Therapeutics could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics of similar companies.Celldex Therapeutics is currently under evaluation in net income category among its peers.
Celldex Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Celldex Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Celldex Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Celldex Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Celldex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Celldex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Celldex Therapeutics' value.| Shares | Vestal Point Capital Lp | 2025-06-30 | 1.8 M | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Eventide Asset Management, Llc | 2025-06-30 | 1.4 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.3 M | Polar Capital Holdings Plc | 2025-06-30 | 1.2 M | Novo A/s | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 841.2 K | Eversept Partners, Llc | 2025-06-30 | 838.7 K | Kynam Capital Management, Lp | 2025-06-30 | 6.1 M | Blackrock Inc | 2025-06-30 | 5.6 M |
Celldex Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (98.59) % | ||||
| Current Valuation | 943.75 M | ||||
| Shares Outstanding | 66.45 M | ||||
| Shares Owned By Insiders | 0.19 % | ||||
| Shares Owned By Institutions | 99.81 % | ||||
| Number Of Shares Shorted | 9.24 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 2.62 X | ||||
| Price To Sales | 586.51 X | ||||
| Revenue | 7.02 M | ||||
| Gross Profit | (214.08 M) | ||||
| EBITDA | (191.9 M) | ||||
| Net Income | (157.86 M) | ||||
| Cash And Equivalents | 356.82 M | ||||
| Cash Per Share | 7.63 X | ||||
| Total Debt | 3.81 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.29 X | ||||
| Book Value Per Share | 9.01 X | ||||
| Cash Flow From Operations | (157.78 M) | ||||
| Short Ratio | 13.44 X | ||||
| Earnings Per Share | (3.38) X | ||||
| Target Price | 53.36 | ||||
| Number Of Employees | 186 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 1.52 B | ||||
| Total Asset | 792.34 M | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 707.66 M | ||||
| Current Asset | 294.94 M | ||||
| Current Liabilities | 30.24 M | ||||
| Net Asset | 792.34 M |
About Celldex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celldex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.